RxDoctor Payments Data

Vanh Luangphakdy, MD

Internal Medicine · Sarasota, FLNPI 1487834172

Payments from drug & device makers

$3,819in general payments, 2019–2025

Across 207 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$564
  • GSK$500
  • Bayer$469
  • Exact Sciences$410
  • Amgen$393
  • Novo Nordisk$340
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,819 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$320,014
Medicare patients
526
Services billed
4,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$106,176
EliquisApixaban111$95,590
JardianceEmpagliflozin71$81,278
Tresiba Flextouch U-200Insulin Degludec27$49,756
JanuviaSitagliptin Phosphate33$32,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$26,936
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$25,422
LinzessLinaclotide19$18,667
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$9,977
Novolog FlexpenInsulin Aspart36$7,275
Atorvastatin Calcium502$4,758
Albuterol Sulfate HfaAlbuterol Sulfate142$4,529
Arnuity ElliptaFluticasone Furoate12$4,032
Simvastatin495$3,654
Losartan Potassium314$2,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$340$106,176101 claims
PfizerEliquis, Paxlovid$136$97,019141 claims
Boehringer IngelheimJardiance$136$81,27871 claims
MerckJanuvia$55$32,88833 claims
GSKTrelegy Ellipta, Arnuity Ellipta$500$30,96828 claims
AbbVieLinzess, Synthroid$115$21,03147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →